Elanco Animal Health (NYSE:ELAN) CFO Acquires 4,200 Shares

Elanco Animal Health Incorporated (NYSE:ELAN) CFO Robert Vanhimbergen bought 4,200 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $23.08 per share, with a total value of $96,936.00. Following the completion of the purchase, the chief financial officer owned 137,516 shares in the company, valued at approximately $3,173,869.28. The trade was a 3.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Elanco Animal Health Stock Performance

NYSE ELAN traded up $0.14 during midday trading on Monday, hitting $22.26. The company had a trading volume of 22,469,851 shares, compared to its average volume of 5,703,481. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The stock has a market cap of $11.12 billion, a price-to-earnings ratio of -54.29, a P/E/G ratio of 1.32 and a beta of 1.67. The firm has a fifty day simple moving average of $24.70 and a two-hundred day simple moving average of $24.08. Elanco Animal Health Incorporated has a fifty-two week low of $16.89 and a fifty-two week high of $27.98.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Equities analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors have recently added to or reduced their stakes in ELAN. Parallel Advisors LLC raised its position in Elanco Animal Health by 5.9% in the fourth quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after acquiring an additional 392 shares during the period. Sapient Capital LLC grew its position in shares of Elanco Animal Health by 0.3% during the 2nd quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock valued at $3,164,000 after acquiring an additional 420 shares during the period. Lazard Asset Management LLC grew its position in shares of Elanco Animal Health by 0.6% during the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock valued at $1,631,000 after acquiring an additional 425 shares during the period. Northwestern Mutual Investment Management Company LLC increased its stake in shares of Elanco Animal Health by 0.4% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after purchasing an additional 428 shares during the last quarter. Finally, Meeder Advisory Services Inc. raised its holdings in shares of Elanco Animal Health by 4.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after purchasing an additional 510 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on ELAN. UBS Group upped their price target on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday. KeyCorp lifted their price objective on Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. TD Cowen upped their target price on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Finally, Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Elanco Animal Health currently has an average rating of “Moderate Buy” and an average price target of $29.09.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.